The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
 
Charles Joel Rosser
Employment - Nonagen Bioscience
Leadership - Nonagen Bioscience
Stock and Other Ownership Interests - NantKwest,; Nonagen Bioscience
Research Funding - Dendreon
 
Yosuke Hirasawa
No Relationships to Disclose
 
Jared David Acoba
Research Funding - Tesaro
 
David Jon Tamura
No Relationships to Disclose
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Jeffrey Huang
No Relationships to Disclose
 
Mark C. Scholz
No Relationships to Disclose
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Noxopharm; Roche; Seagen
Speakers' Bureau - Exelixis; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb